- Home
- DMAC vs GLSI Comparison
DMAC vs GLSI Comparison
Compare DMAC & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- GLSI
- Stock Information
- Founded
- DMAC 2000
- GLSI 2006
- Country
- DMAC United States
- GLSI United States
- Employees
- DMAC N/A
- GLSI N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- DMAC Health Care
- GLSI Health Care
- Exchange
- DMAC Nasdaq
- GLSI Nasdaq
- Market Cap
- DMAC 158.1M
- GLSI 133.4M
- IPO Year
- DMAC N/A
- GLSI 2020
- Fundamental
- Price
- DMAC $4.11
- GLSI $9.85
- Analyst Decision
- DMAC Strong Buy
- GLSI Strong Buy
- Analyst Count
- DMAC 2
- GLSI 1
- Target Price
- DMAC $8.00
- GLSI $39.00
- AVG Volume (30 Days)
- DMAC 102.4K
- GLSI 37.8K
- Earning Date
- DMAC 05-13-2025
- GLSI 05-20-2025
- Dividend Yield
- DMAC N/A
- GLSI N/A
- EPS Growth
- DMAC N/A
- GLSI N/A
- EPS
- DMAC N/A
- GLSI N/A
- Revenue
- DMAC N/A
- GLSI N/A
- Revenue This Year
- DMAC N/A
- GLSI N/A
- Revenue Next Year
- DMAC N/A
- GLSI N/A
- P/E Ratio
- DMAC N/A
- GLSI N/A
- Revenue Growth
- DMAC N/A
- GLSI N/A
- 52 Week Low
- DMAC $2.14
- GLSI $8.06
- 52 Week High
- DMAC $6.82
- GLSI $18.75
- Technical
- Relative Strength Index (RSI)
- DMAC 50.90
- GLSI 50.03
- Support Level
- DMAC $3.92
- GLSI $9.59
- Resistance Level
- DMAC $4.33
- GLSI $10.10
- Average True Range (ATR)
- DMAC 0.29
- GLSI 0.54
- MACD
- DMAC 0.02
- GLSI 0.03
- Stochastic Oscillator
- DMAC 56.79
- GLSI 43.28
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.